[Cited FineTest Antibody] Current Research on Cancer Therapy

FineTest VEGFR2 antibody contributes to the research on cancer therapy.

Publication Details
Article Title: New-generation cytopharmaceuticals with powerfully boosted extravasation for enhanced cancer therapy
Journal Title: Journal of Controlled Release
DOI: 10.1016/j.jconrel.2023.05.037
IF: 11.467
PMID: 37263546

Abstract: Effective extravasation of therapeutic agents into solid tumors still faces huge challenges. Since the doubted effectiveness of enhanced penetration and retention effect, first-generation neutrophil cytopharmaceuticals with encapsulated drugs have been developed to improve the drug accumulation in tumors based on the active chemotaxis and extravasation of neutrophils. Herein, a new generation of neutrophil cytopharmaceuticals with enhanced tumor-specific extravasation is reported to satisfy more complex clinical demands. This neutrophil cytopharmaceutical is obtained by anchoring vascular endothelial growth factor receptor 2 (VEGFR2)-targeting peptide K237 on neutrophil membrane after endocytosis of chemotherapeutics by neutrophils. Leveraging the cytokine-mediated active migration of neutrophils, the specific-recognition of K237 peptide to tumor vascular endothelium expedites the migration and enhances tight adhesion of neutrophils to vascular endothelium, thus improving the extravasation of therapeutic agents to target sites. Moreover, anti-angiogenesis effect from VEGFR2-blocking by K237 peptide achieves a cooperative tumor destruction with cytotoxic effects from released chemotherapeutics. This study demonstrates the great potential of enhanced proactive extravasation of cytopharmaceuticals via a cell-anchoring technology, leading to expedited drug infiltration and boosted therapeutic effects, which can be applied in other cell therapies to improve efficacy.

Keywords: Anti-angiogenesis, Cell membrane-anchoring strategy, Chemotherapeutics, Enhanced extravasation, Neutrophil cytopharmaceuticals

Illustration

Figure source:  J Control Release. 2023 Jun 7;359:116-131. doi: 10.1016/j.jconrel.2023.05.037.